FDA Grants Extra Time for VAFSEO Patent Monopoly
Published Date: 6/16/2025
Notice
Summary
The FDA has officially set the review period for VAFSEO, a human drug product, so its patent can be extended. This helps the drug maker get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive and valuable.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent Extension Eligibility for VAFSEO
The FDA has set the regulatory review period for the human drug product VAFSEO and published that determination. If you own or manage the patent for VAFSEO, this lets you submit applications to the U.S. Patent and Trademark Office to extend that patent and get extra protected time after the drug approval process.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in